Adverse effects of drugs used to treat hematologic malignancies: Surveillance efforts from the research on adverse drug events and reports project

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 4, 2007, Pages 365-372

  Bennett, Charles L ^a,b,c,d,e   Tigue, Cara C ^a,b,c   Angelotta, Cara ^a,b,c   McKoy, June M ^d   Edwards, Beatrice J ^a,d  

^a JESSE BROWN VA MEDICAL CENTER   (United States)

^b NW Univ Feinberg School of Medicine   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adverse drug reactions; Drug surveillance; Hematologic malignancies; Pharmaceutical safety

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CETUXIMAB; DEXAMETHASONE; DOXORUBICIN; GEFITINIB; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MITOXANTRONE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PAMIDRONIC ACID; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE; TIOGUANINE; TRASTUZUMAB; WARFARIN; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; BONE NECROSIS; CARDIOTOXICITY; COMBINATION CHEMOTHERAPY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOMAGNESEMIA; INTERSTITIAL PNEUMONIA; LEUKEMIA; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; LUNG CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELOMA; PRIORITY JOURNAL; PURE RED CELL ANEMIA; REVIEW; SKIN TOXICITY; THROMBOEMBOLISM; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; DRUG TOXICITY; HEMATOLOGIC NEOPLASMS; HUMANS; MULTICENTER STUDIES; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34249931317     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-976172     Document Type: Review

References (32)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279(15):1200-1205
2. Ladewski LA, Belknap SM, Nebeker JR, et al. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol 2003;21(20):3859-3866
3. Lasser KE, Seger DL, Yu DT, et al. Adherence to black box warnings for prescription medications in outpatients. Arch Intern Med 2006;166(3):338-344
4. Fast Track. Accelerated approval and priority review: accelerating availability of new drugs for patients with serious diseases. U.S. Food and Drug Administration May 2006. http://www.fda.gov/oashi/fast.html#accelerated. Accessed November 27, 2006
5. Trontell A. Expecting the unexpected - drug safety, pharmacovigilance, and the prepared mind. N Engl J Med 2004; 351(14):1385-1387
6. Smalley W, Shatin D, Wysowski DK, et al. Contraindicatcd use of cisapride: impact of food and drug administration regulatory action. JAMA 2000;284(23):3036-3039
7. Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002;99(7):2599-2602
8. Graf G, Zaborski M, Quentmeier H, Drexler HG. Phorbol ester PMA induces expression of the thrombopoietin receptor MPL in leukemia cells. Leuk Lymphoma 1996;24(1-2):149-157
9. Kessler DA. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA 1993;269(21):2765-2768
10. Almenoff J, Tonning JM, Gould AL, et al. Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf 2005;28(11):981-1007
11. Sargent DJ, Goldberg RM, Mahoney MR, et al. Rapid reporting and review of an increased incidence of a known adverse event. J Natl Cancer Inst 2000;92(12):1011-1013
12. Soares H, Kumar A, Djulbegovic B. Quality of reporting of harms in NCl sponsored phase III hematological malignancies trials. Blood 2005;106: (abst 292)
13. Bennett CL, Nebeker JR, Lyons EA, et al. The Research on Adverse Drug Events and Reports (RADAR) project. JAMA 2005;293(17):2131-2140
14. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351(14): 1403-1408
15. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with Clopidogrel. N Engl J Med 2000;342(24):1773-1777
16. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002;99(7):2310-2314
17. Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003;102(5):1578-1582
18. Cohen AD, Luger SM, Sickles C, et al. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant 2002;30(1):23-28
19. McKoy JM, Angelotta C, Bennett CL, et al. Gemtuzumab ozogamicin- associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 2006 (September):7 (Epub ahead of print)
20. Bennett CL, Angelotta C, Yarnold PR, et al. Thalidomide-and lenalidomide-associated thromboembolism among patients with cancer. JAMA 2006;296(21):2558-2560
21. Dimopoulos M, Spencer A, Atfal M, et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010). Blood 2005;106: (abst 6)
22. Food and Drug Administration. Lenalidomide package insert. Available at: http://www.fda.gov/cder/foi/label/2006/021880s001.pdf. Accessed September 6, 2006
23. Food and Drug Administration. Thalidomide package insert. Available at: http://www.fda.gov/cder/foi/label/2006/021430s000,020785s031lbl.pdf. Accessed September 6, 2006
24. Bennett CL, Schumock GT, Desai AA, et al. Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med 2002;113(7):603-606
25. Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006;354(19): 2079-2080
26. Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006;354(19):2079-2080
27. Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006;108(1):403 (author reply 404)
28. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4(8):459-460
29. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362(9392):1255-1260
30. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287(17):2215-2220
31. Trontell AE. The RADAR project and the FDA. JAMA 2005;294(10):1206 (author reply 1206-1207)
32. Waxman HA. The lessons of Vioxx - drug safety and sales. N Engl J Med 2005;352(25):2576-2578